

Silexion's SIL204 showed strong KRAS-targeted inhibition across pancreatic, colorectal, and lung cancer cells, supporting its advancement to clinical trials.
You can purchase shares of Silexion Therapeutics (NASDAQ:SLXN) through any online brokerage.
Other companies in Silexion Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Silexion Therapeutics has a consensus price target of $405.00.
The stock price for Silexion Therapeutics (NASDAQ: SLXN) is $0.17885 last updated October 26, 2026 at 11:34 AM EDT.
There are no upcoming dividends for Silexion Therapeutics.
Silexion Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Silexion Therapeutics.
Silexion Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene...